J 2011

Clinical Relevance of uPA, uPAR, PAI 1 and PAI 2 Tissue Expression and Plasma PAI 1 Level in Colorectal Carcinoma Patients

HALÁMKOVÁ, Jana; Igor KISS; Zdeněk PAVLOVSKÝ; Jiří JARKOVSKÝ; Jiří TOMÁŠEK et al.

Základní údaje

Originální název

Clinical Relevance of uPA, uPAR, PAI 1 and PAI 2 Tissue Expression and Plasma PAI 1 Level in Colorectal Carcinoma Patients

Vydání

Hepatogastroenterology, 2011, 0172-6390

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30000 3. Medical and Health Sciences

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 0.658

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/11:00055477

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Colorectal cancer; Plasminogen activator system; PAI 1; PAI 2; uPA; uPAR

Příznaky

Mezinárodní význam
Změněno: 9. 2. 2012 07:35, Mgr. Michal Petr

Anotace

V originále

Urokinase (uPA) is a serine protease, which together with uPAR, tPA, PAI 1 and PAI 2 forms the plasminogen activator system, a component of metastatic cascade contributing to the invasive growth and angiogenesis of malignant tumours. Methodology: Both preceding therapy and after 6-8 weeks of the treatment, plasma PAI 1 levels (photometric microplate method on the ELISA) and uPA, uPAR, PAI 1 and PAI 2 tissue expression (immunohistochemical reaction) were analysed from 80 colorectal carcinoma patients. Results: Analysis showed higher pre-treatment plasma levels of PAI 1 in patients with advanced tumours, which decreased after surgery or the start of therapy (p=0.004); Patients with higher plasma level PAI 1 before (0.013) and after therapy (0.004) had significantly shorter survival. There was a higher expression of uPA (p<0.001), uPAR (p<0.001), PAI 1 (p=0.042) and PAI 2 (p<0.001) in advanced colorectal carcinoma. A relationship between PAI 2 (p=0.010) and uPAR (p=0.019) expression and survival was demonstrated. There is a correlation between pre-treatment plasma PAI 1 levels and PAI 2 (p=0.028) and uPAR (p=0.043) expression. Conclusions: Immunohistochemical analysis of PAS in tumour tissue and plasma PAI 1 levels was found to be a useful prognostic factor in colorectal carcinoma patients. Plasma PAI 1 could be advantageous in evaluating the effectiveness of a mode of treatment.